Alloparc wrote: While I usually take analyst coverage with a grain of salt, I will say one thing: they pointed out something that I personally hadn't even considered:
** Jefferies starts coverage on Canadian cannabis producer Aphria Inc with 'buy', sets PT at C$15
** Says despite a strong global outlook, co's valuation is the cheapest
** Sees governance-related issues, which weighed on co's valuation, fading; a short-seller had raised questions on insider dealing
** Says co's capacity outlook is compelling especially in extraction and that APHA's approach to recreational cannabis has been impressive
** "Areas where Aphria is potentially trailing its closest peers are U.S. optionality and work in the space of genetics/bio-tech" - brokerage
** Says, in the United States co may do what it did in Germany - buy non-cannabis assets for leveraging at a later date
IMO, that's actually not a bad play. I just have no idea who a target could be that would be similar to Pharma CC.
Either way, nice to see the strong open today. I think the bump is more related to just being oversold (and not the analyst coverage), but I'll take it. Maybe we can get some PR to help support the move up? Maybe? Aphria... give us something! Please? :p